Rybrevant

(Amivantamab)

Phase 3Monoclonal antibody

This medication is a type of immunotherapy that helps your body's immune system fight certain lung cancers by slowing or stopping the growth of cancer cells.[1] Rybrevant is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]

Rybrevant is one of 313 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

312

Competitors

Pipeline

Status by Indication[3][1]

Indication

Salivary Gland CancerActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

Adenoid Cystic CarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Gastric CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Salivary Gland CancerPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

Adenoid Cystic CarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 3

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Rybrevant

Johnson & Johnson

Phase 3

9 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Vidaza

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Small Cell Lung Cancer

NCT04988295

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05601973

Q4 2026

Phase 2Recruiting

Cancer

NCT03767075

Phase 2Active, not recruiting

Gastric Cancer

NCT05117931

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT02609776

Q1 2027

Phase 1Recruiting

Advanced Solid Malignancies

NCT06507306

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung11 trials

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04487080·1,074 enrolled

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + Lazertinib

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06120140·305 enrolled

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07586202·68 enrolled

Show 8 more trials

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT07227025·60 enrolled

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT05908734·71 enrolled

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06667076·480 enrolled

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04077463·701 enrolled

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04538664·308 enrolled

Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05663866·68 enrolled

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05498428·520 enrolled

61186372PANSC2003: 61186372PANSC2003 ISA#3 Platform Trial

Completed· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT06532032·12 enrolled

Non-Small Cell Lung Cancer9 trials

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04965090·43 enrolled

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT05601973·60 enrolled

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT05488314·57 enrolled

Show 6 more trials

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Approved for marketing· Johnson & Johnson logo

Johnson & Johnson··NCT04599712

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06083857·3 enrolled

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Active, not recruiting·LLatin American Cooperative Oncology Group·Phase 2·NCT05299125·54 enrolled

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05801029·60 enrolled

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT06116682·88 enrolled

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02609776·751 enrolled

Colorectal Neoplasms2 trials

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06662786·1,000 enrolled

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06750094·700 enrolled

Squamous Cell Carcinoma of Head and Neck2 trials

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT06385080·287 enrolled

A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07276399·500 enrolled

Advanced Solid Malignancies1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06507306·100 enrolled

13 more indications

Small Cell Lung Cancer1 trial

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04988295·776 enrolled

Tumour1 trial

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1·NCT06632236·12 enrolled

Adenoid Cystic Carcinoma1 trial

Amivantamab in Adenoid Cystic Carcinoma

Active, not recruiting·TTrisha Wise-Draper·Phase 2·NCT05074940·18 enrolled

Cancer1 trial

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT03767075·1,000 enrolled

Colorectal Cancer1 trial

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT05845450·197 enrolled

Hepatocellular Carcinoma1 trial

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT05653427·18 enrolled

Esophageal Cancer1 trial

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04945733·62 enrolled

Lung Cancer1 trial

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

Recruiting·UUniversity Hospital, Essen·Phase 2·NCT06784791·20 enrolled

Chemotherapy1 trial

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

Recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT07392658·33 enrolled

Gastric Cancer1 trial

A Study of Amivantamab in People With Esophagogastric Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05117931·25 enrolled

Tyrosine Kinase Inhibitors1 trial

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Active, not recruiting·UUniversity of Colorado, Denver·Phase 1/2·NCT05845671·12 enrolled

Metastatic Colorectal Cancer1 trial

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT05379595·225 enrolled

Advanced or Metastatic Non-small Cell Lung Cancer1 trial

A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05388669·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Amivantamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amivantamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amivantamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor; Hepatocyte Growth Factor Receptor Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Rybrevant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung11 trials

Non-Small Cell Lung Cancer9 trials

Colorectal Neoplasms2 trials

Squamous Cell Carcinoma of Head and Neck2 trials

Advanced Solid Malignancies1 trial

Small Cell Lung Cancer1 trial

Tumour1 trial

Adenoid Cystic Carcinoma1 trial

Cancer1 trial

Colorectal Cancer1 trial

Hepatocellular Carcinoma1 trial

Esophageal Cancer1 trial

Lung Cancer1 trial

Chemotherapy1 trial

Gastric Cancer1 trial

Tyrosine Kinase Inhibitors1 trial

Metastatic Colorectal Cancer1 trial

Advanced or Metastatic Non-small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News